ECM-Affinity Cytokine Conjugates for Tumor Localization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, such as chemotherapy and radiation therapy, have limitations in efficacy and toxicity, and direct administration of cytokines for cancer therapy can be toxic systemically, necessitating a need for compositions and methods that target cytokines to specific areas like tumors to enhance efficacy and reduce side effects.
Innovation Solution
Development of cytokines operatively linked to extracellular matrix (ECM)-affinity peptides, particularly collagen-binding domains, to target and localize therapy in tumors, utilizing peptides from von Willebrand Factor (vWF) or decorin to enhance tumor-specific delivery and reduce systemic exposure.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cytokines are administered systemically for cancer therapy, then anti-tumor efficacy is improved, but systemic toxicity increases
Solution Approach 1:
The cytokine is modified to have different properties in different locations: it maintains full activity at the tumor site through ECM-binding localization, while being effectively absent from systemic circulation. This is achieved by fusing the cytokine to an ECM-affinity peptide that targets it specifically to the tumor microenvironment, creating local high concentration where needed while avoiding systemic exposure and toxicity
Solution Approach 2:
An ECM-affinity peptide acts as an intermediary between the cytokine and the tumor tissue. This peptide mediates the targeted delivery of the cytokine to the tumor by binding to extracellular matrix components at the tumor site, enabling the cytokine to reach its target without requiring systemic administration and thereby avoiding systemic toxicity
2Reliability
If high doses of cytokines are used to overcome resistance, then anti-tumor efficacy is improved, but toxicity increases
Solution Approach 1:
The fusion construct creates a localized high concentration of active cytokine at the tumor site without requiring high systemic doses. The ECM-binding domain ensures that even low systemic doses result in high local concentrations at the tumor, overcoming resistance through local saturation while avoiding systemic toxicity associated with high dose administration
3Reliability
If cytokines are administered to ensure adequate tumor penetration, then anti-tumor efficacy is improved, but systemic exposure and side effects increase
Solution Approach 1:
The cytokine-ECM fusion construct achieves superior tumor penetration through active targeting via ECM-binding, creating high local concentration within the tumor interstitium. This targeted approach ensures adequate penetration without requiring high systemic doses, thereby achieving effective tumor delivery while minimizing systemic side effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The ECM-affinity peptide-linked cytokines effectively localize to tumors, reducing the required dose and minimizing systemic toxicity, thereby enhancing treatment efficacy and safety for cancers like melanoma and colon cancer.
Implementation Method 1
ECM-affinity peptide is one that has affinity for and binds to an extracellular matrix protein, such as collagen
Implementation Method 2
Certain embodiments are directed to the administration of a cancer therapy that localizes in a tumor due to vascular permeability of the tumor
Data Source
AI summary
The methods and compositions described herein address the need in the art by providing compositions and methods for a therapy with a cytokine that is specifically targeted to and/or retained intra- or peri-tumorally, limiting systemic exposure and reducing side-effects. Accordingly, aspects of the disclosure relate to a composition comprising an immunotherapeutic antibody operatively linked to an extracellular matrix (ECM)-affinity peptide. An ECM-affinity peptide is one that has affinity for an extracellular matrix protein.